Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Our department is developing novel approaches for immunotherapy, and we closely collaborate with our clinical colleagues to advance important discoveries to clinical trials.
We are also closely collaborating with our clinical colleagues to advance the development of novel cancer immunotherapies. We are developing novel technology platforms (including mass cytometry, CyTOF) for in-depth characterization of immune cell populations
in human cancers and experimental animal models. We believe that this technology will substantially enhance our ability to study immunological mechanisms in patients enrolled in clinical trials of novel immunotherapies. We are also working on a novel
technique for isolation of therapeutic antibodies from patients who respond to immunotherapies, based on the observation that such patients can mount immune responses against inhibitory immune molecules (Wucherpfennig and Dranoff Labs).
Isolation of antibodies from cancer patients responding to immunotherapies (Blood 2011, 118:348,